Takeda Pharmaceutical (TKPHF) Share-based Compensation (IS) (2018 - 2026)

Takeda Pharmaceutical's Share-based Compensation (IS) history runs 9 years deep, the most recent figure standing at $125.7 million for Q1 2026.

• In Q1 2026, Share-based Compensation (IS) rose 8.79% year-over-year to $125.7 million; the TTM figure through Mar 2026 stood at $482.7 million (up 0.73% YoY), while the FY2026 annual figure was $483.5 million, up 1.07% from the prior year.
• Share-based Compensation (IS) was $125.7 million for Q1 2026 at Takeda Pharmaceutical, up from $115.7 million in the prior quarter.
• In the past five years, Share-based Compensation (IS) ranged from a high of $144.5 million in Q3 2024 to a low of $95.0 million in Q2 2022.
• Historically, Share-based Compensation (IS) has averaged $117.5 million across 5 years, with a median of $116.7 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation (IS) gained 21.73% in 2022, then slipped 12.28% in 2024.
• A 5-year view of Share-based Compensation (IS) shows it stood at $116.7 million in 2022, then climbed by 8.43% to $126.6 million in 2023, then slipped by 4.88% to $120.4 million in 2024, then slipped by 3.9% to $115.7 million in 2025, then grew by 8.66% to $125.7 million in 2026.
• The last three Share-based Compensation (IS) figures came in at $125.7 million (Q1 2026), $115.7 million (Q4 2025), and $127.1 million (Q3 2025), per Business Quant data.